Impact of NaCl on Monoclonal Antibody Aggregation Induced by Agitation

References

1. 1.↵
   1. Reichert J. M.

   Marketed Therapeutic Antibodies Compendium. MAbs 2012, 4 (3), 413–415.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Buss N. A. P. S.,
   2. Henderson S. J.,
   3. McFarlane M.,
   4. Shenton J. M.,
   5. de Haan L.

   Monoclonal Antibody Therapeutics: History and Future. Curr. Opin. Pharmacol. 2012, 12 (5), 615–622.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mahler H.-C.,
   2. Friess W.,
   3. Grauschopf U.,
   4. Kiese S.

   Protein Aggregation: Pathways, Induction Factors and Analysis. J. Pharm. Sci. 2009, 98 (9), 2909–2934.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Li J.,
   2. Krause M. E.,
   3. Chen X.,
   4. Cheng Y.,
   5. Dai W.,
   6. Hill J. J.,
   7. Huang M.,
   8. Jordan S.,
   9. LaCasse D.,
   10. Narhi L.,
   11. Shalaev E.,
   12. Shieh I. C.,
   13. Thomas J. C.,
   14. Tu R.,
   15. Zheng S.,
   16. Zhu L.

   Interfacial Stress in the Development of Biologics: Fundamental Understanding, Current Practice, and Future Perspective. AAPS J. 2019, 21 (3), 44.

   OpenUrl
5. 5.↵
   1. Shieh I. C.,
   2. Patel A. R.

   Predicting the Agitation-Induced Aggregation of Monoclonal Antibodies Using Surface Tensiometry. Mol. Pharmaceutics 2015, 12 (9), 3184–3193.

   OpenUrl
6. 6.↵
   1. Narhi L. O.,
   2. Schmit J.,
   3. Bechtold-Peters K.,
   4. Sharma D.

   Classification of Protein Aggregates. J. Pharm. Sci. 2012, 101 (2), 493–498.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Patten P. A.,
   2. Schellekens H.

   The Immunogenicity of Biopharmaceuticals. Lessons Learned and Consequences for Protein Drug Development. Dev. Biol. (Basel, Switz.) 2003, 112, 81–97.

   OpenUrl
8. 8.↵
   1. Schellekens H.

   Immunogenicity of Therapeutic Proteins: Clinical Implications and Future Prospects. Clin. Ther. 2002, 24 (11), 1720–1740. discussion 1719.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Joubert M. K.,
   2. Hokom M.,
   3. Eakin C.,
   4. Zhou L.,
   5. Deshpande M.,
   6. Baker M. P.,
   7. Goletz T. J.,
   8. Kerwin B. A.,
   9. Chirmule N.,
   10. Narhi L. O.,
   11. Jawa V.

   Highly Aggregated Antibody Therapeutics Can Enhance the In Vitro Innate and Late-Stage T-Cell Immune Responses. J. Biol. Chem. 2012, 287 (30), 25266–25279.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Rosenberg A. S.

    Effects of Protein Aggregates: An Immunologic Perspective. AAPS J. 2006, 8 (3), E501–E507.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Carpenter J. F.,
    2. Randolph T. W.,
    3. Jiskoot W.,
    4. Crommelin D. J. A.,
    5. Middaugh C. R.,
    6. Winter G.,
    7. Fan Y.-X.,
    8. Kirshner S.,
    9. Verthelyi D.,
    10. Kozlowski S.,
    11. Clouse K. A.,
    12. Swann P. G.,
    13. Rosenberg A.,
    14. Cherney B.

    Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. J. Pharm. Sci. 2009, 98 (4), 1201–1205.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Kessler M.,
    2. Goldsmith D.,
    3. Schellekens H.

    Immunogenicity of Biopharmaceuticals. Nephrol., Dial., Transplant. 2006, 21 (Suppl 5), v9–v12.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Wood C. V.,
    2. Razinkov V. I.,
    3. Qi W.,
    4. Furst E. M.,
    5. Roberts C. J.

    A Rapid, Small-Volume Approach to Evaluate Protein Aggregation at Air-Water Interfaces. J. Pharm. Sci. 2021, 110 (3), 1083–1092.

    OpenUrl
14. 14.↵
    1. Koepf E.,
    2. Eisele S.,
    3. Schroeder R.,
    4. Brezesinski G.,
    5. Friess W.

    Notorious but Not Understood: How Liquid-Air Interfacial Stress Triggers Protein Aggregation. Int. J. Pharm. 2018, 537 (1-2), 202–212.

    OpenUrl
15. 15.↵
    1. Bee J. S.,
    2. Randolph T. W.,
    3. Carpenter J. F.,
    4. Bishop S. M.,
    5. Dimitrova M. N.

    Effects of Surfaces and Leachables on the Stability of Biopharmaceuticals. J. Pharm. Sci. 2011, 100 (10), 4158–4170.

    OpenUrl
16. 16.↵
    1. Jayaraman M.,
    2. Buck P. M.,
    3. Ignatius A. A.,
    4. King K. R.,
    5. Wang W.

    Agitation-Induced Aggregation and Subvisible Particulate Formation in Model Proteins. Eur. J. Pharm. Biopharm. 2014, 87 (2), 299–309.

    OpenUrl
17. 17.↵
    1. Sieffert N.,
    2. Wipff G.

    Importance of Interfacial Adsorption in the Biphasic Hydroformylation of Higher Olefins Promoted by Cyclodextrins: A Molecular Dynamics Study at the Decene/Water Interface. Chem. – Eur. J. 2007, 13 (7), 1978–1990.

    OpenUrl
18. 18.↵
    1. Vaclaw C.,
    2. Merritt K.,
    3. Pringle V.,
    4. Whitaker N.,
    5. Gokhale M.,
    6. Carvalho T.,
    7. Pan D.,
    8. Liu Z.,
    9. Bindra D.,
    10. Khossravi M.,
    11. Bolgar M.,
    12. Volkin D. B.,
    13. Ogunyankin M. O.,
    14. Dhar P.

    Impact of Polysorbate 80 Grade on the Interfacial Properties and Interfacial Stress Induced Subvisible Particle Formation in Monoclonal Antibodies. J. Pharm. Sci. 2021, 110 (2), 746–759.

    OpenUrl
19. 19.↵
    1. Wood C. V.,
    2. McEvoy S.,
    3. Razinkov V. I.,
    4. Qi W.,
    5. Furst E. M.,
    6. Roberts C. J.

    Kinetics and Competing Mechanisms of Antibody Aggregation via Bulk- and Surface-Mediated Pathways. J. Pharm. Sci. 2020, 109 (4), 1449–1459.

    OpenUrl
20. 20.↵
    1. Kannan A.,
    2. Shieh I. C.,
    3. Fuller G. G.

    Linking Aggregation and Interfacial Properties in Monoclonal Antibody-Surfactant Formulations. J. Colloid Interface Sci. 2019, 550, 128–138.

    OpenUrl
21. 21.↵
    1. Khan T. A.,
    2. Mahler H.-C.,
    3. Kishore R. S. K.

    Key Interactions of Surfactants in Therapeutic Protein Formulations: A Review. Eur. J. Pharm. Biopharm. 2015, 97 (Part A), 60–67.

    OpenUrlCrossRef
22. 22.↵
    1. Tein Y. S.,
    2. Zhang Z.,
    3. Wagner N. J.

    Competitive Surface Activity of Monoclonal Antibodies and Nonionic Surfactants at the Air-Water Interface Determined by Interfacial Rheology and Neutron Reflectometry. Langmuir 2020, 36 (27), 7814–7823.

    OpenUrl
23. 23.↵
    1. Gamage C. L. D.,
    2. Weis D. D.,
    3. Walters B. T.

    Identification of Agitation-Induced Unfolding Events Causing Aggregation of Monoclonal Antibodies Using Hydrogen Exchange-Mass Spectrometry. J. Pharm. Sci. 2022, 111 (8), 2210–2216.

    OpenUrl
24. 24.↵
    1. Vargo K. B.,
    2. Stahl P.,
    3. Hwang B.,
    4. Hwang E.,
    5. Giordano D.,
    6. Randolph P.,
    7. Celentano C.,
    8. Hepler R.,
    9. Amin K.

    Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension to Predict Surfactant Requirements for Biological Formulations. Mol. Pharmaceutics 2021, 18 (1), 148–157.

    OpenUrl
25. 25.↵
    1. Wang W.

    Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals. Int. J. Pharm. 1999, 185 (2), 129–188.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Goswami S.,
    2. Wang W.,
    3. Arakawa T.,
    4. Ohtake S.

    Developments and Challenges for mAb-Based Therapeutics. Antibodies 2013, 2 (4), 452–500.

    OpenUrl
27. 27.↵
    1. Arosio P.,
    2. Jaquet B.,
    3. Wu H.,
    4. Morbidelli M.

    On the Role of Salt Type and Concentration on the Stability Behavior of a Monoclonal Antibody Solution. Biophys. Chem. 2012, 168–169, 19–27.

    OpenUrl
28. 28.↵
    1. Nicoud L.,
    2. Arosio P.,
    3. Sozo M.,
    4. Yates A.,
    5. Norrant E.,
    6. Morbidelli M.

    Kinetic Analysis of the Multistep Aggregation Mechanism of Monoclonal Antibodies. J. Phys. Chem. B 2014, 118 (36), 10595–10606.

    OpenUrl
29. 29.↵
    1. Imamura H.,
    2. Honda S.

    Kinetics of Antibody Aggregation at Neutral pH and Ambient Temperatures Triggered by Temporal Exposure to Acid. J. Phys. Chem. B 2016, 120 (36), 9581–9589.

    OpenUrl
30. 30.↵
    1. De Young L. R.,
    2. Fink A. L.,
    3. Dill K. A.

    Aggregation of Globular-Proteins. Acc. Chem. Res. 1993, 26 (12), 614–620.

    OpenUrlCrossRef
31. 31.↵
    1. Vicsek T.

    Fractal Growth Phenomena, 2nd ed.; World Scientific: Singapore; New Jersey, 1992.
32. 32.↵
    1. Harshe Y. M.,
    2. Ehrl L.,
    3. Lattuada M.

    Hydrodynamic Properties of Rigid Fractal Aggregates of Arbitrary Morphology. J. Colloid Interface Sci. 2010, 352 (1), 87–98.

    OpenUrlPubMed
33. 33.↵
    1. Vlasak J.,
    2. Ionescu R.

    Fragmentation of Monoclonal Antibodies. MAbs 2011, 3 (3), 253–263.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Nicoud L.,
    2. Sozo M.,
    3. Arosio P.,
    4. Yates A.,
    5. Norrant E.,
    6. Morbidelli M.

    Role of Cosolutes in the Aggregation Kinetics of Monoclonal Antibodies. J. Phys. Chem. B 2014, 118 (41), 11921–11930.

    OpenUrl
35. 35.↵
    1. Xia Y.,
    2. Ouyang J.

    Salt-Induced Charge Screening and Significant Conductivity Enhancement of Conducting Poly(3,4-Ethylenedioxythiophene):Poly(Styrenesulfonate). Macromolecules 2009, 42 (12), 4141–4147.

    OpenUrlCrossRef
36. 36.↵
    1. Kannan A.,
    2. Shieh I. C.,
    3. Hristov P.,
    4. Fuller G. G.

    In-Use Interfacial Stability of Monoclonal Antibody Formulations Diluted in Saline i.v. Bags. J. Pharm. Sci. 2021, 110 (4), 1687–1692.

    OpenUrl
37. 37.↵
    1. Li Y.,
    2. Weiss W.F. IV.,
    3. Roberts C. J.

    Characterization of High-Molecular-Weight Nonnative Aggregates and Aggregation Kinetics by Size Exclusion Chromatography with Inline Multi-Angle Laser Light Scattering. J. Pharm. Sci. 2009, 98 (11), 3997–4016.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Li Y.,
    2. Roberts C. J.

    Lumry-Eyring Nucleated-Polymerization Model of Protein Aggregation Kinetics. 2. Competing Growth via Condensation and Chain Polymerization. J. Phys. Chem. B 2009, 113 (19), 7020–7032.

    OpenUrlPubMed